Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Tocris Bioscience™ JNJ 1013

Click to view available options
Quantity:
5 mg
Description
JNJ 1013 is a potent interleukin 1 receptor associated kinase 1 (IRAK1) PROTAC™ Degrader (DC50 = 3 nM; Dmax = 96%). In ABC DLBCL cell lines with MyD88 L265P mutation, JNJ 1013 potently inhibits IRAK1 downstream signaling pathways, induces apoptosis, and shows strong anti-proliferative effects. PROTAC™ is a registered trademark of Arvinas Operations, Inc., and is used under license.
Specifications
Specifications
Chemical Name or Material | N-(4-(4-(2-(((S)-1-((2S,4R)-4-Hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)piperidin-1-yl)-2-methoxyphenyl)-6-(1H-pyrazol-5-yl)picolinamide |
CAS | 2597343-08-1 |
Quantity | 5 mg |
Target | Active Degraders |
Molecular Formula | C46H55N9O7S |
Purity | 98% |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction